186 Financial Statements Principal Subsidiaries Percentage of voting At 31 December 2009 Country share capital held Principal activity UK AstraZeneca UK Limited England 100 Research and development, manufacturing, marketing AstraZeneca Treasury Limited England 100 Treasury Continental Europe NV AstraZeneca SA Belgium 100 Marketing AstraZeneca Dunkerque Production SCS France 95 Manufacturing AstraZeneca SAS France 100 Research, manufacturing, marketing AstraZeneca GmbH Germany 100 Development, manufacturing, marketing AstraZeneca Holding GmbH Germany 100 Manufacturing, marketing AstraZeneca SpA Italy 100 Marketing AstraZeneca Farmaceutica Spain SA Spain 100 Marketing AstraZeneca AB Sweden 100 Research and development, manufacturing, marketing AstraZeneca BV The Netherlands 100 Marketing The Americas AstraZeneca Canada Inc. Canada 100 Research, marketing AZ Reinsurance Limited Cayman Islands 100 Insurance and reinsurance underwriting IPR Pharmaceuticals Inc. Puerto Rico 100 Development, manufacturing, marketing AstraZeneca LP US 99 Research and development, manufacturing, marketing AstraZeneca Pharmaceuticals LP US 100 Research and development, manufacturing, marketing Zeneca Holdings Inc.
US 100 Manufacturing, marketing MedImmune, LLC US 100 Research and development, manufacturing, marketing Asia, Africa & Australasia AstraZeneca Pty Limited Australia 100 Development, manufacturing, marketing AstraZeneca Pharmaceuticals Co. Limited China 100 Research and development, manufacturing, marketing AstraZeneca KK Japan 80 Manufacturing, marketing All shares are held indirectly.
The companies and other entities listed above are those whose results or financial position principally affected the figures shown in the Group Financial Statements.
A full list of subsidiaries, joint ventures and associates will be annexed to the Companys next annual return filed with the Registrar of Companies.
The country of registration or incorporation is stated alongside each company.
The accounting year ends of subsidiaries and associates are 31 December, except for Aptium Oncology, Inc. which, owing to local conditions and to avoid undue delay in the preparation of the Financial Statements, is 30 November.
AstraZeneca operates through 282 subsidiaries worldwide.
Products are manufactured in 18 countries worldwide and are sold in over 100 countries.
The Group Financial Statements consolidate the Financial Statements of the Company and its subsidiaries at 31 December 2009.
AstraZeneca Annual Report and Form 20-F Information 2009
